Altogen
Biosystems is a recognized provider and laboratory for the pharmaceutical
industry. Custom research services and additional goods include xenografts,
cell transfection optimization, 28-day generation of stably-transfected cells,
IND applications and more. Dedicated to assisting customers with cutting-edge
and efficient services, Altogen Biosystems endeavors to advance modern
laboratory techniques. Visit the official website for a Caki-1 xenograft model.
Clear cell renal cell carcinoma (ccRCC) is one of the most common urological cancers diagnosed globally. Two cell lines that derive from human ccRCC are Caki-1 and Caki-2, which express wild-type VHL (von Hippel-Lindau). Defining characteristics of ccRCC include the mutation of the VHL tumor suppressor gene and the overexpression of hypoxia-inducible factor (HIF)-1 α protein. Previous studies have suggested that metformin (a drug used to treat diabetes) exhibit antineoplastic effects in different types of cancers since its activation of AMPK evidently decreases the expression of HIF-1 α. In this study, researchers analyze the effect of metformin on both Caki-1 and Caki-2 cell lines. Several concentrations of Metformin were used to treat the cell lines, and various assays and analyses were used to observe cell viability, cell cycle arrest, migration, and apoptosis. Results from this study indicate that Metformin inhibited cell growth in both Caki-1 and Caki-2 cell lines. Howe...
Comments
Post a Comment